سعر ساندوستاتين لار 30مجم فيال عضل + سرنجة معبأة 2024

Octreotide 30 mg long-acting release powder for intramuscular injectable suspension (Sandostatin LAR, Novartis): 1 vial with prefilled diluent syringe.

• Long-term maintenance therapy in acromegaly (inadequate response to, or unsuitable for, surgery and/or radiotherapy) in patients who responded to and tolerated Sandostatin Injection.DailyMed (U.S. National Library of Medicine)
• Long-term treatment of severe diarrhoea and flushing associated with metastatic carcinoid tumours.DailyMed (U.S. National Library of Medicine)
• Long-term treatment of profuse watery diarrhoea associated with VIP-secreting tumours (VIPomas).DailyMed (U.S. National Library of Medicine)

• Most common (≥20%): acromegaly – diarrhoea, cholelithiasis, abdominal pain, flatulence; carcinoid syndrome – back pain, fatigue, headache, abdominal pain, nausea, dizziness.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None stated in the US label.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cholelithiasis and its complications (monitor periodically, stop if complications suspected); hypo- or hyperglycaemia (monitor glucose, adjust antidiabetic therapy); hypothyroidism (monitor thyroid function); bradycardia, arrhythmias and conduction abnormalities; steatorrhoea and fat malabsorption; reduced vitamin B12 levels.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CiclosporinOctreotide may decrease ciclosporin blood levels and result in transplant rejection.DailyMed (U.S. National Library of Medicine)
• Insulin and oral hypoglycaemic agentsOctreotide inhibits insulin and glucagon secretion; monitor blood glucose and adjust antidiabetic therapy.DailyMed (U.S. National Library of Medicine)
• Beta-blockers and other bradycardia-inducing drugsPossible additive reduction in heart rate; dose adjustment may be needed.DailyMed (U.S. National Library of Medicine)

• Limited data in pregnant women are insufficient to inform a drug-associated risk; no adverse developmental effects in rats and rabbits at 7–13 times the MRHD; transient growth retardation in rat offspring.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk or effects on the breastfed infant; octreotide passes into rat milk at low concentration.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Octreotide (as acetate): Cyclic octapeptide somatostatin analogue that inhibits secretion of growth hormone, glucagon, insulin, serotonin, gastrin, VIP and other gastroenteropancreatic peptides.